Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Neuronal Plasticity Clinical Trial

Official title:

Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02753738
• Other study ID #: 21042016
• Status: Not yet recruiting
• Phase: Phase 4
• First received: April 21, 2016
• Last updated: April 25, 2016
• Start date: August 2016

Study information

• Verified date: April 2016
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Agency for Health and Food Safety
• Study type: Interventional

Clinical Trial Summary

Background:

Conclusive evidence states that the serotonergic system mediates neuroplasticity from early embryonic development until brain maturation in adulthood. This study aims to demonstrate that selective serotonin reuptake inhibitors (SSRIs) enhance learning-dependent neuroplasticity in vivo, hereby contributing to the investigators understanding of the mechanism of action of therapy with SSRIs.

Objectives:

1. To prove a positive influence of SSRIs on structural remodeling during learning, reflected by enhancements of gray and white matter microstructure, connectivity and functionality in brain regions involved in learning processes.

2. To show that this effect is topologically specific, i.e. that enhancements of plasticity markers are found in different regions depending on their involvement during the performance of specific learning tasks.

Study design:

Randomized, double-blind, placebo-controlled, longitudinal mono-center study. 80 healthy subjects will undergo three MRI scanning sessions: 1. baseline, at study entry, 2. after 3 weeks of facial/emotional (n=40) or Chinese character-meaning learning (n=40) and 3. after 3 weeks learning of new associations under administration of an SSRI or placebo.

Methods:

MRI measurements will be performed on a 3 Tesla PRISMA MAGNETOM MR scanner. Changes in gray matter microstructure will be assessed using high-resolution structural MRI and analyzed with voxel-based morphometry (VBM). Diffusion tensor imaging (DTI) enables non-invasive investigation of neuroplasticity in the human brain based on the reduction in mean diffusivity associated with swelling of astrocytes after increased synaptic activity. Resting-state functional MRI (fMRI) will allow for the measurement of changes in functional coupling between brain regions, and fMRI during tasks will assess differential activity in brain regions during learning.

Relevance and implications:

This study aims to provide evidence that SSRIs facilitate cytoarchitectonical restructuring. In addition to expanding the investigators current knowledge on the trophic effects of SSRIs, the results of this study will also elucidate interactions between the serotonergic system and changes to neuronal networks during learning as well as their behavioral consequences. By probing the neurobiological correlates of the antidepressant and anti-anxiety effects of SSRIs, this study will provide a rationale for targeted interventions that harness the neuroplasticity enhancing properties of SSRIs to facilitate therapeutic processes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. primary completion date: August 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID)

• Willingness and competence to sign the informed consent form

• Right-handedness

• Non-smoker, and non-alcohol drinker

Exclusion Criteria:

• Any medical, psychiatric or neurological illness

• Current or former substance abuse

• Any implant or stainless steel graft or any other contraindications for MRI

• First degree relatives with a history of psychiatric illness or substance abuse

• Color blindness, any Chinese language skills

• Failure to comply with the study protocol or to follow the instructions of the investigating team

• Lifetime use of SSRIs or related psychotropic agents

• Non-Caucasian

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Neuronal Plasticity
• Ssri

Intervention

Drug:
• Escitalopram
Tablet 10mg, 21 days
• Placebo
Tablet, 21 days

Other:
• 3xMR scan (fMRI, DTI, strucutral MRI)
3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms

Behavioral:
• Association learning paradigm
21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
• Association re-learning paradigm
21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment

Locations

Country	Name	City	State
Austria	Department of Psychiatry and Psychotherapy, Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gray matter volume	voxel based morphometry (T1 weighted MPRAGE sequence)	21 days	No
Primary	Mean diffusivity	diffusion tensor imaging	21 days	No
Secondary	BOLD signal	functional MRI (learning paradigms)	21 days	No